MNV NS1/2 Viral Region Restores Gut Microbiota Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective approaches for treating dysbiosis and associated disorders in the gastrointestinal tract, particularly in response to antibiotic exposure and infections, and there is a need for novel therapeutic strategies that can modulate the immune system and enhance mucosal integrity.
Innovation Solution
The use of the NS1/2 genomic region of murine norovirus MNV or corresponding regions from the Caliciviridae family, or proteins encoded by these regions, administered therapeutically to treat dysbiosis, immune system dysregulation, and various disorders, including inflammatory and metabolic conditions, by stimulating antibacterial defenses and enhancing mucosal integrity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If antibiotics are used to treat bacterial infections, then bacterial infections are eliminated, but gastrointestinal dysbiosis and immune system dysregulation occur
Solution Approach 1:
The patent utilizes the NS1/2 viral proteins, which naturally stimulate immune responses, to convert the harmful effect of immune dysregulation caused by antibiotics into a beneficial therapeutic effect. The viral proteins restore immune balance and promote beneficial microbiota growth, transforming the post-antibiotic inflammatory state into a restorative process that reestablishes gastrointestinal health.
2Ease of manufacture
If conventional therapies are used for dysbiosis, then treatment is provided, but effective approaches are lacking
Solution Approach 1:
The patent extracts and utilizes only the essential NS1/2 protein regions from the viral genome, separating the therapeutic immune-stimulating components from the rest of the viral structure. This extraction allows for focused delivery of the active immunomodulatory elements that specifically address dysbiosis and immune dysregulation, providing an effective treatment mechanism that conventional therapies lack.
Data Source
AI summary
The present invention relates to the use of NS1/2 region of murine norovirus MNV or a corresponding region from a member of the Caliciviridae family or a protein encoded by any one of those regions, for treating dysbiosis, immune system dysregulation and various disorders, as well as for enhancing mucosal integrity and stimulating IFN-induced genes.